Literature DB >> 16023974

Chronic hepatitis C: genotypes 4 to 9.

Mindie H Nguyen1, Emmet B Keeffe.   

Abstract

Infection with hepatitis C virus (HCV) genotypes 1, 2, or 3 is widely distributed throughout the world and has been the focus of the majority of studies on the epidemiology and treatment of chronic hepatitis C. Infection with HCV genotypes 4 through 9 is prevalent in some geographic areas where the disease burden of chronic hepatitis C approaches endemic levels (eg, HCV genotype 4 in Egypt where there is an HCV infection prevalence of approximately 18%). This article reviews the existing literature, which suggests that chronic hepatitis C with genotypes 4 through 9 may exhibit epidemiologic, clinical, and treatment outcome differences from infection with genotypes 1, 2, or 3.

Entities:  

Mesh:

Year:  2005        PMID: 16023974     DOI: 10.1016/j.cld.2005.05.010

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  18 in total

Review 1.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

2.  Elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations.

Authors:  Iman H Bassyouni; Rasha H Bassyouni; Nermin H Ibrahim; Ahmed F Soliman
Journal:  J Clin Immunol       Date:  2012-06-24       Impact factor: 8.317

Review 3.  2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-08-10

Review 4.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 5.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

6.  Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans.

Authors:  Nghia H Nguyen; Philip Vutien; Huy N Trinh; Ruel T Garcia; Long H Nguyen; Huy A Nguyen; Khanh K Nguyen; Mindie H Nguyen
Journal:  Hepatol Int       Date:  2010-04-09       Impact factor: 6.047

7.  Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin.

Authors:  Brittany E Yee; Nghia H Nguyen; Bing Zhang; Philip Vutien; Carrie R Wong; Glen A Lutchman; Mindie H Nguyen
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-11       Impact factor: 2.566

8.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

9.  Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.

Authors:  Roberto J Carvalho-Filho; Olav Dalgard
Journal:  Pharmgenomics Pers Med       Date:  2010-03-11

10.  Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains.

Authors:  Xia Rong; Ling Lu; Junzhi Wang; Huaping Xiong; Jieting Huang; Jinyan Chen; Ke Huang; Ru Xu; Min Wang; Xuemei Zhang; Tai Guo; Yueyue Liu; Guoquan Gao; Yongshui Fu; Kenrad E Nelson
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.